Mycobacterium tuberculosis chaperonin 60.1 is a more potent cytokine stimulator than chaperonin 60.2 (Hsp 65) and contains a CD14-binding domain

被引:98
作者
Lewthwaite, JC
Coates, ARM
Tormay, P
Singh, M
Mascagni, P
Poole, S
Roberts, M
Sharp, L
Henderson, B
机构
[1] UCL, Eastman Dent Inst, Cellular Microbiol Res Grp, London WC1X 8LD, England
[2] St George Hosp, Sch Med, Dept Med Microbiol, London, England
[3] Natl Inst Biol Stand & Controls, Div Endocrinol, Potters Bar EN6 3QG, Herts, England
[4] TU Braunschweig, Dept Biochem, GBF, Braunschweig, Germany
[5] Lionex GmbH, Braunschweig, Germany
[6] Italfarmaco SpA, Ctr Ric, Cinisello Balsamo, MI, Italy
关键词
D O I
10.1128/IAI.69.12.7349-7355.2001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Much attention has focused on the Mycobacterium tuberculosis molecular chaperone chaperonin (Cpn) 60.2 (Hsp 65) in the pathology of tuberculosis because of its immunogenicity and ability to directly activate human monocytes and vascular endothelial cells. However, M. tuberculosis is one of a small group of bacteria that contain multiple genes encoding Cpn 60 proteins. We have now cloned and expressed both M. tuberculosis proteins and report that the novel chaperonin 60, Cpn 60.1, is a more potent inducer of cytokine synthesis than is Cpn 60.2. This is in spite of 76% amino acid sequence similarity between the two mycobacterial chaperonins. The M. tuberculosis Cpn 60.2 protein activates human peripheral blood mononuclear cells by a CD14-independent mechanism, whereas Cpn 60.1 is partially CD14 dependent and contains a peptide sequence whose actions are blocked by anti-CD14 monoclonal antibodies. The cytokine-inducing activity of both chaperonins is extremely resistant to heat. Cpn 60.1 may be an important virulence factor in tuberculosis, able to activate cells by diverse receptor-driven mechanisms.
引用
收藏
页码:7349 / 7355
页数:7
相关论文
共 28 条
[1]   HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine [J].
Asea, A ;
Kraeft, SK ;
Kurt-Jones, EA ;
Stevenson, MA ;
Chen, LB ;
Finberg, RW ;
Koo, GC ;
Calderwood, SK .
NATURE MEDICINE, 2000, 6 (04) :435-442
[2]   Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity [J].
Beutler, B .
CURRENT OPINION IN MICROBIOLOGY, 2000, 3 (01) :23-28
[3]  
Coates Anthony R. M., 1996, P267, DOI 10.1016/B978-012237455-5/50011-7
[4]   CHAPERONIN NOMENCLATURE [J].
COATES, ARM ;
SHINNICK, TM ;
ELLIS, RJ .
MOLECULAR MICROBIOLOGY, 1993, 8 (04) :787-787
[5]   AIDS VACCINE PREDICTIONS [J].
COATES, ARM ;
COOKSON, J ;
BARTON, GJ ;
ZVELEBIL, MJ ;
STERNBERG, MJE .
NATURE, 1987, 326 (6113) :549-550
[6]   AUTOIMMUNITY, MICROBIAL IMMUNITY AND THE IMMUNOLOGICAL HOMUNCULUS [J].
COHEN, IR ;
YOUNG, DB .
IMMUNOLOGY TODAY, 1991, 12 (04) :105-110
[7]   JPred: a consensus secondary structure prediction server [J].
Cuff, JA ;
Clamp, ME ;
Siddiqui, AS ;
Finlay, M ;
Barton, GJ .
BIOINFORMATICS, 1998, 14 (10) :892-893
[8]   Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country [J].
Dye, C ;
Scheele, S ;
Dolin, P ;
Pathania, V ;
Raviglione, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :677-686
[9]  
FRIEDLAND JS, 1993, CLIN EXP IMMUNOL, V91, P58
[10]   HOMOLOGOUS PLANT AND BACTERIAL PROTEINS CHAPERONE OLIGOMERIC PROTEIN ASSEMBLY [J].
HEMMINGSEN, SM ;
WOOLFORD, C ;
VANDERVIES, SM ;
TILLY, K ;
DENNIS, DT ;
GEORGOPOULOS, CP ;
HENDRIX, RW ;
ELLIS, RJ .
NATURE, 1988, 333 (6171) :330-334